Effectiveness of ultrasound therapy in the complex spa treatment of non-alcoholic fatty liver disease
https://doi.org/10.31146/1682-8658-ecg-212-4-70-76
Abstract
The purpose of the study is to study the effectiveness of sanatorium-resort treatment of NAFLD with the use of balneo-drinking intake of MW and its combination with ultrasound therapy. Materials and methods: There have been observed 80 patients with a verified diagnosis of NAFLD, of both sexes, at the age of 52.8 (47, 3; 59, 6) years old. Two groups of 40 people were formed by simple randomization - a control group (CG), its patients were prescribed traditional balneo-drinking treatment by MW “Slavyanovskaya”, and a group of comparison (GC) who additionally had ultrasound therapy (UST) on the projection of the liver. The effectiveness of the treatment was assessed by the dynamics of clinical symptoms, indicators of the functional state of the liver (total bilirubin level, activity of cytolysis and cholestasis enzymes), as well as the parameters of the speed characteristics of portal blood flow. Results: comparative analysis showed that in the group of comparison, positive changes in clinical manifestations of the disease were 10% higher than in the control group (p < 0.05). Favorable shifts in liver function tests were observed in the CG in 67.5% by 15.6% - 27.2%, and in the GC - in 75% by 30.2% - 40.4% with significant differences (p < 0.01). Normalization of the velocity parameters of portal blood flow was observed in the CG - 67.5% by 6.3% - 8.5%, and in the GC - 77.5% by 7.6% - 12.1% (p < 0.05). Conclusion. The inclusion of UST in the traditional complex of spa treatment of patients with NAFLD contributes to a significant increase in the favorable effect of MW on the dynamics of clinical symptoms, liver function tests and portal blood flow with an increase in the overall effectiveness of the treatment by 10% due to the mutual and comparative effect of MW and ultrasound therapy.
About the Authors
N. V. Efimenko
North Caucasian Federal Scientific and Clinical Centre of Federal Medical and Biological Agency
Russian Federation
Russian Federation
T. M. Simonova
North Caucasian Federal Scientific and Clinical Centre of Federal Medical and Biological Agency
Russian Federation
Russian Federation
E. N. Chalaya
North Caucasian Federal Scientific and Clinical Centre of Federal Medical and Biological Agency
Russian Federation
Russian Federation
V. V. Kolomeitsev
Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
References
1. Krolevets T. S., Livzan M. A. Non-alcoholic fatty liver disease: digest 2021.Russian Journal of evidence-based Gastroenterology. 2021;10(2):27-35. (in Russ.) doi: 10.17116/dokgastro20211002127.@@ Кролевец Т. С., Ливзан М. А. Неалкогольная жировая болезнь печени: дайджест 2021. Доказательная гастроэнтерология. 2021;10(2):27-35. doi: 10.17116/dokgastro20211002127.
2. Maev I. V., Andreev D. N., Kucheryavy Yu.A., Dicheva D. T., Kuznetsova E. I. [Non-alcoholic fatty liver disease from the standpoint of modern medicine]. Moscow. Prima Print, 2020. 68 p. (in Russ.)@@ Маев И. В., Андреев Д. Н., Кучерявый Ю. А., Дичева Д. Т., Кузнецова Е. И. Неалкогольная жировая болезнь печени с позиций современной медицины. М.: Прима Принт, 2020. 68 с.
3. Vinnitskaya E. V., Sandler Yu.G., Bordin D. S. The new paradigm of non-alcoholic fatty liver disease: phenotypic diversity of metabolically associated fatty liver disease. Effective Pharmacotherapy. 2020;16(24):54-63. (in Russ.) doi: 10.33978/2307-3586-2020-16-24-54-63.@@ Винницкая Е. В., Сандлер Ю. Г., Бордин Д. С. Новая парадигма неалкогольной жировой болезни печени: фенотипическое многообразие метаболически ассоциированной жировой болезни печени. Эффективная фармакотерапия. 2020;16(24):54-63. doi: 10.33978/2307-3586-2020-16-24-54-63.
4. Younossi Z., Tacke F., Arrese M., Chander Sharma B., Mostafa I., Bugianesi E. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology. 2019;69(6):2672-82. doi: 10.1002/hep.30251.
5. Mitra S., De A., Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Hepatology. 2020;5(5):16. doi: 10.21037/tgh.2019.09.08.
6. Roitberg G. E., Sharkhun O. O. Assessment of risk factors for non-alcoholic fatty liver disease. Lechashchij vrach. 2017;(1):58-61. (in Russ.)@@ Ройтберг Г. Е., Шархун О. О. Оценка факторов риска неалкогольной жировой болезни печени. Лечащий врач. 2017;(1):58-61.
7. Balukova E. V., Uspensky Yu.P., Fominykh Yu. A. Liver diseases of various genesis (toxic, drug-induced, dysmetabolic): from etiological heterogenicity to a single unified therapy of patients. RMJ. Medical review. 2018;2(1-1):35-40. (in Russ.)@@ Балукова Е. В., Успенский Ю. П., Фоминых Ю. А. Поражения печени различного генеза (токсического, лекарственного, дисметаболического): от этиологической гетерогенности к единой унифицированной терапии пациентов. Русский медицинский журнал. Медицинское обозрение. 2018;2(1-1):35-40.
8. Abd El-Kader S.M., El-Den Ashmawy E. M. Non-alcoholic fatty liver disease: The diagnosis and management. World Journal of Hepatology. 2015;7(6):846-58. doi: 10.4254/wjh.v7.i6.846.
9. Lazebnik L. B., Radchenko V. G., Dzhadhav S. N., Sitkin S. I., Seliverstov P. V. Systemic inflammation and non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2019;165(5): 29-41. (in Russ.) doi: 10.31146/1682-8658-ecg-165-5-29-41.@@ Лазебник Л. Б., Радченко В. Г., Джадхав С. Н., Ситкин С. И., Селиверстов П. В. Системное воспаление и неалкогольная жировая болезнь печени. Экспериментальная и клиническая гастроэнтерология. 2019;165(5):29-41. doi: 10.31146/1682-8658-ecg-165-5-29-41.
10. Maksimov V. A., Dalidovich K. K., Fedoruk A. M., Morozkina T. S., Kulikov A. G. [Diseases of civilization: systemic metabolic lesions]. Moscow. Adamant, 2020. 671 p. (in Russ.)@@ Максимов В. А., Далидович К. К., Федорук А. М., Морозкина Т. С., Куликов А. Г. Болезни цивилизации: системные метаболические поражения. М.: «АдамантЪ», 2020. 671 с.
11. Buzzetti E., Pinzani M., Tsochatzis E. A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038-1048. doi: 10.1016/j.metabol.2015.12.012.
12. Romero-Gómez M., Zelber-Sagi S., Trenell M. Treatment of NAFLD with diet, physical activity and exercise. Journal of Hepatology. 2017;67(4):829-46. doi: 10.1016/j.jhep.2017.05.016.
13. Nikonov E. L., Aksenov V. A. Current approaches to diagnosing and treating nonalcoholic fatty liver disease. The Russian Journal of Preventive Medicine. 2018;21(3):62-69. (in Russ.) doi: 10.17116/profmed201831262.@@ Никонов Е. Л., Аксенов В. А. Современные подходы к диагностике и лечению неалкогольной жировой болезни печени. Профилактическая медицина. 2018;21(3):62-6. doi: 10.17116/profmed201831262.
14. Abramtsova A. V., Efimenko N. V., Reps V. F., Soprun D. S. Theoretical substantiation of correction of metabolic syndrome by natural mineral waters in the perspective of experimental research. Resort medicine. 2017;(4):16-9. (in Russ.)@@ Абрамцова А. В., Ефименко Н. В., Репс В. Ф., Сопрун Д. С. Теоретическое обоснование коррекции метаболического синдрома природными минеральными водами в перспективе экспериментальных исследований. Курортная медицина. 2017;(4):16-9.
15. Fedorova T. E., Efimenko N. V., Ortabaeva M. H., Demchenko V. P., Muhotin N. A. PSpa Treatment of Nonalcoholic Fatty Liver Disease in Patients with Metabolic Syndrome with Drinking Mineral Water of Essentuki Type Applications. Medical Herald of the South of Russia. 2012;(4):58-61. (In Russ.)@@ Федорова Т. Е., Ефименко Н. В., Ортабаева М. Х., Демченко В. П., Мухотин Н. А. Курортная терапия неалкогольной жировой болезни печени у больных с метаболическим синдромом с применением питьевых минеральных вод Ессентукского типа. Медицинский вестник Юга России: 2012;4:58-61.
16. Simonova T. M., Efimenko N. V., Kaisinova A. S., Kolomeytsev V. V., Leonchuk A. L. Non-alcoholic fatty liver disease - connection with metabolic syndrome, methods of spa therapy. Bulletin of physiotherapy and balneology. 2021;27(3):66-70. (in Russ.) doi: 10.37279/2413-0478-2021-27-3-66-70.@@ Симонова Т. М., Ефименко Н. В., Кайсинова А. С., Коломейцев В. В., Леончук А. Л. Неалкогольная жировая болезнь печени - связь с метаболическим синдромом, методики курортной терапии. Вестник физиотерапии и курортологии. 2021;27(3):66-70. doi: 10.37279/2413-0478-2021-27-3-66-70.
17. Azov S. Kh., Kuryanov A. K. Ultrasound therapy and drug ultraphonophoresis.International Journal of Experimental Education. 2015;12(1):133-5. (in Russ.)@@ Азов С. Х., Курьянов А. К. Ультразвуковая терапия и лекарственный ультрафонофорез. Международный журнал экспериментального образования. 2015;12(1):133-5.
18. Abramovich S. G. [Ultrasound therapy. A guide for doctors]. Irkutsk. 2015. 44 p. (in Russ.)@@ Абрамович С. Г. Ультразвуковая терапия. Пособие для врачей. Иркутск. 2015. 44 c.
Review
For citations:
Efimenko N.V., Simonova T.M., Chalaya E.N., Kolomeitsev V.V. Effectiveness of ultrasound therapy in the complex spa treatment of non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2023;(4):70-76. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-212-4-70-76
Views:
283
Email this article 